Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.
about
Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal CancerIntestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic ConstipationPlecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC miceNovel investigational drugs for constipation-predominant irritable bowel syndrome: a review.Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.Plecanatide: First Global Approval.GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.Comparative Evaluation between Sulfasalazine Alone and in Combination with Herbal Medicine on DSS-Induced Ulcerative Colitis Mice.Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.GUCY2C maintains intestinal LGR5+ stem cells by opposing ER stress.Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.Formulary Drug Reviews: Plecanatide.Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice.Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation.Clinical utility of plecanatide in the treatment of chronic idiopathic constipationThe Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia
P2860
Q28071957-FB1E20C0-86E3-4976-8D04-2A40F83CDE14Q30815469-023285F4-3F0B-4857-BF23-4E201BB473F3Q33634439-927F1E04-C705-4FB3-B974-8097AB2B5A9BQ34551599-F06A19A6-9BE3-414F-B769-2659CB71C1F5Q38696256-399FE5C9-44ED-4123-A354-116FF3F0DAC7Q39120155-3F378FB1-A9E5-4DB4-9EA2-ACB68D787E9DQ39159463-7DFF41D9-EEFF-42A3-BDB3-656903DA27BBQ41925319-056704AE-866D-4BF1-9C16-145AB88AE31EQ42177619-12BF881A-92A0-4466-9BF1-465BC490BF61Q42293861-6A287C2B-19CF-4AF8-B61A-5E513BDB6D2FQ47136609-0617832D-5B53-4627-AE5C-9D7A8D3BCA93Q49359806-EDEF2E1E-02AC-4175-88DC-E46A5082637DQ49587169-D44DA0E1-B01B-48E8-8E74-7D718F0B163DQ53187152-C5AA3E61-4764-4DF1-9B78-3FEC09C9114FQ55245208-DF9D5F91-7057-485F-9213-CD3635B6209CQ55259850-EE8F2705-13B9-4E86-8E5D-BFBD27C2DAADQ58790572-8CF0643F-8640-4780-97AA-788314E5CB3FQ58798789-F0BE9E89-FBC4-4EB8-B79A-83799D8CC578
P2860
Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Plecanatide and dolcanatide, n ...... ntal models of murine colitis.
@ast
Plecanatide and dolcanatide, n ...... ntal models of murine colitis.
@en
type
label
Plecanatide and dolcanatide, n ...... ntal models of murine colitis.
@ast
Plecanatide and dolcanatide, n ...... ntal models of murine colitis.
@en
prefLabel
Plecanatide and dolcanatide, n ...... ntal models of murine colitis.
@ast
Plecanatide and dolcanatide, n ...... ntal models of murine colitis.
@en
P2093
P2860
P356
P1476
Plecanatide and dolcanatide, n ...... ntal models of murine colitis.
@en
P2093
Bradley Nefsky
Gary S Jacob
John A Foss
Krishna Priya Arjunan
Kunwar Shailubhai
Sayali Saykhedkar
Scott E Plevy
Stephen Comiskey
Vaseem Palejwala
P2860
P304
P356
10.4292/WJGPT.V6.I4.213
P577
2015-11-01T00:00:00Z